HomeCompareNVRO vs MRK

NVRO vs MRK: Dividend Comparison 2026

NVRO yields 34.25% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NVRO wins by $110.9K in total portfolio value
10 years
NVRO
NVRO
● Live price
34.25%
Share price
$5.84
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$168.6K
Annual income
$25,000.88
Full NVRO calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — NVRO vs MRK

📍 NVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNVROMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NVRO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NVRO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NVRO
Annual income on $10K today (after 15% tax)
$2,910.96/yr
After 10yr DRIP, annual income (after tax)
$21,250.75/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, NVRO beats the other by $12,654.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NVRO + MRK for your $10,000?

NVRO: 50%MRK: 50%
100% MRK50/50100% NVRO
Portfolio after 10yr
$113.2K
Annual income
$17,557.33/yr
Blended yield
15.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NVRO
Analyst Ratings
9
Buy
19
Hold
4
Sell
Consensus: Hold
Price Target
$30.32
+419.2% upside vs current
Range: $4.00 — $125.00
Altman Z
-0.6
Piotroski
2/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NVRO buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNVROMRK
Forward yield34.25%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$168.6K$57.7K
Annual income after 10y$25,000.88$10,113.78
Total dividends collected$120.7K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$30.32$128.54

Year-by-year: NVRO vs MRK ($10,000, DRIP)

YearNVRO PortfolioNVRO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$14,125$3,424.66$11,213$373.04+$2.9KNVRO
2$19,634$4,520.76$12,667$512.06+$7.0KNVRO
3$26,882$5,873.02$14,439$708.14+$12.4KNVRO
4$36,278$7,514.85$16,640$988.16+$19.6KNVRO
5$48,296$9,478.22$19,432$1,394.07+$28.9KNVRO
6$63,469$11,792.55$23,057$1,992.90+$40.4KNVRO
7$82,395$14,483.60$27,889$2,894.79+$54.5KNVRO
8$105,736$17,572.52$34,518$4,286.29+$71.2KNVRO
9$134,212$21,075.04$43,912$6,494.35+$90.3KNVRO
10$168,608$25,000.88$57,714$10,113.78+$110.9KNVRO

NVRO vs MRK: Complete Analysis 2026

NVROStock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Full NVRO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NVRO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NVRO vs SCHDNVRO vs JEPINVRO vs ONVRO vs KONVRO vs MAINNVRO vs JNJNVRO vs ABBVNVRO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.